Mounjaro®
Starting from £179.99/mo
Start journey Learn moreMounjaro (tirzepatide) has a half-life of roughly five days, which means active drug levels in your body do fall noticeably in the days before your next injection. Many people find appetite and fullness signals are slightly weaker on days five, six or seven compared with days one and two. That late-week dip is real, it is pharmacologically expected, and understanding it can make the whole treatment easier to manage. These are prescription-only medicines, and a GPhC-registered prescriber reviews every consultation before any treatment is approved — so the patterns described here are worth raising during that conversation.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
After a subcutaneous injection, tirzepatide is absorbed slowly through the tissue beneath the skin. Levels in the bloodstream rise over the first day or two, reach a broad peak, then begin a gradual decline. Because the half-life sits at roughly five days, by the time day seven arrives the concentration in your system is meaningfully lower than it was on day two. That decline is what lies behind the question most people are really asking: why do I feel hungrier on Friday when I inject on Monday?
This is not the medicine failing. It is how once-weekly subcutaneous drugs behave by design. The NHS's tirzepatide page explains the general pharmacology in plain language and is worth bookmarking alongside the printed Patient Information Leaflet that comes with every pen.
What it means in practice is that the dual GIP and GLP-1 receptor signalling that slows gastric emptying and reduces appetite is at its most consistent in the middle of the week, and slightly attenuated in the day or two before the next dose. If you have noticed this pattern yourself, our guide covering whether Mounjaro wears off at the end of the week looks at exactly what is happening and why. Most people find this levels out over several weeks as steady-state concentrations build up across repeated injections.
The early weeks of treatment (particularly at the 2.5 mg starting dose) tend to produce the most noticeable end-of-week contrast. That starting dose exists primarily to let your system adjust and minimise gastrointestinal side effects; it is not the dose at which most of the appetite-regulating work happens. As the prescriber titrates upward and the body reaches a pharmacokinetic steady state, the trough-to-peak ratio narrows. In other words, the gap between how you feel on day two and how you feel on day seven tends to shrink.
Keeping your injection on the same day each week is the single most practical step you can take. A consistent schedule (whether that is Monday morning before the kettle goes on or Saturday evening after dinner) prevents the interval drifting to eight or nine days, which would widen the trough further. Many people also find it helpful to read about how Mounjaro's effects can shift towards the end of the week, particularly if they are trying to decide whether what they are experiencing is typical. If the late-week dip is still noticeably affecting your eating patterns after several dose increases, that is exactly the kind of detail worth logging and sharing with your prescriber at your next review.
People sometimes wonder whether switching injection day could help. That is a clinical question rather than something to do unilaterally, changing the day is fine in principle but needs to be handled in a way that avoids either a gap that is too long or two doses too close together. Your prescriber will advise on the safest way to make that adjustment.
A mild increase in hunger or a slight reduction in the fullness you feel after meals during days six and seven is expected and does not usually need action beyond noting it. What is worth flagging to your clinical team is anything more significant: sustained loss of appetite suppression across most of the week even at a maintenance dose, or side effects that seem to cluster or intensify rather than settle. You can also explore a closer look at when Mounjaro's effects shift during the week to understand the timing in more detail.
It is also worth distinguishing the pharmacological trough from unrelated changes. Stress, disrupted sleep, hormonal shifts (including those tied to the menstrual cycle, a topic covered in depth on our page on Mounjaro and menstrual changes) can all affect appetite independently of where you are in the injection cycle. Keeping a brief weekly log helps both you and your prescriber separate signal from noise.
For a broader grounding in how tirzepatide works across all dimensions of the treatment, the tirzepatide overview sets out the mechanism, the evidence and what the titration schedule looks like in practice. If questions about cost or what to look for in a regulated provider are on your mind, our guide to Mounjaro pricing in the UK covers that ground honestly.
Most people find the end-of-week dip manageable once they know it is coming. Planning slightly more protein-forward meals on days five to seven, keeping well hydrated and not skipping meals in an attempt to compensate are practical approaches, though any specific dietary adjustments are best discussed with a dietitian or your prescriber rather than improvised.
The NICE appraisal of tirzepatide (TA1026) notes that treatment works best alongside reduced-calorie eating and increased physical activity. That lifestyle context matters more, not less, during the trough days.
If you are considering starting treatment and want to understand what clinical oversight looks like from the first consultation onwards, our treatment overview sets out the full process at nume, including how every prescription is reviewed by a named, GPhC-registered prescriber. The weight-loss treatments page gives a broader picture of what is currently available under UK licence. And if you have questions before starting, our frequently asked questions cover a range of common concerns.
When you are ready to talk it through with a clinician, start your free consultation and a prescriber will review your answers the same day.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.